United Therapeutics Corporation or Geron Corporation: Who Invests More in Innovation?

Biotech Giants' R&D Spending: A Decade of Innovation

__timestampGeron CorporationUnited Therapeutics Corporation
Wednesday, January 1, 201420707000242549000
Thursday, January 1, 201517831000245098000
Friday, January 1, 201618047000147600000
Sunday, January 1, 201711033000264600000
Monday, January 1, 201813432000357900000
Tuesday, January 1, 2019520720001182600000
Wednesday, January 1, 202051488000357700000
Friday, January 1, 202185727000540100000
Saturday, January 1, 202295518000322900000
Sunday, January 1, 2023125046000408000000
Loading chart...

Data in motion

Innovation Investment: A Tale of Two Biotech Giants

In the competitive world of biotechnology, innovation is the lifeblood of success. United Therapeutics Corporation and Geron Corporation, two prominent players in the industry, have shown distinct approaches to research and development (R&D) investments over the past decade. From 2014 to 2023, United Therapeutics consistently outpaced Geron in R&D spending, with an average annual investment nearly 8 times higher. Notably, in 2019, United Therapeutics reached a peak, investing over 1.18 billion dollars, a staggering 10-fold increase compared to Geron's expenditure that year. This trend highlights United Therapeutics' commitment to innovation, while Geron has shown a steady increase, culminating in a 6-fold rise in 2023 compared to 2014. As the biotech landscape evolves, these investment strategies may well dictate the future breakthroughs and market leadership of these companies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025